COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)

Jump to navigation Jump to search

Vaccination for Stable COPD

  • Influenza vaccination is recommended for people with COPD (Evidence B).
  • The WHO and CDC recommend SARS-CoV-2 (COVID-19) vaccination for people with COPD (Evidence B).
  • The CDC recommends one dose of 20-valent pneumococcal conjugate vaccine (PCV20) or one dose of 15-valent pneumococcal conjugate vaccine (PCV15) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for people with COPD (Evidence B).
  • Pneumococcal vaccination has been shown to reduce the incidence of community-acquired pneumonia and exacerbations for people with COPD (Evidence B).
  • The CDC recommends the new respiratory syncytial virus (RSV) vaccine for individuals over 60 years and/or with chronic heart or lung disease (Evidence B).
  • The CDC recommends Tdap (dTaP/dTPa) vaccination to protect against pertussis (whooping cough) for people with COPD that were not vaccinated in adolescence (Evidence B), and Zoster vaccine to protect against shingles for people with COPD over 50 years (Evidence B).
Retrieved from "https://www.wikidoc.org/index.php?title=COPD_Patient_with_suspected_Exacerbation(New_GOLD_2024_Recommendation)&oldid=1739180"